MGMT and central nervous system cancer: We performed Multivariate Cox regression analysis (Table 3) for various variables where both MGMT promoter methylation as well as loss of protein its expression were significantly found to be an independent prognostic factors in glioma patients with Hazard Ratio (HR) of death as 4.15 (OS) and 0.82 (PFS) for MGMT methylation (p < 0.05) and 0.73 for expression (p = 0.002).